40647-02-7 Usage
Uses
Used in Pharmaceutical Industry:
BTO-1 is used as a Plk1 inhibitor for targeting the ATP-binding pocket of Plk1, which plays a significant role in cell division and mitosis. By inhibiting Plk1, BTO-1 can potentially be employed in the development of therapeutic strategies for cancer treatment, as abnormal cell division is a hallmark of cancer cells.
Used in Cancer Research:
BTO-1 is used as a research tool for studying the role of Plk1 in cancer cell division and mitosis. Its ability to inhibit Plk1 kinase activity and induce mitosis defects makes it a valuable compound for investigating the molecular mechanisms underlying cancer progression and the potential development of novel cancer therapies.
Used in Drug Development:
BTO-1 is used as a lead compound in the development of new drugs targeting Plk1, which may have applications in various cancer types. Its inhibitory effects on Plk1 activity and its ability to induce mitosis defects make it a promising starting point for the design and synthesis of more potent and selective Plk1 inhibitors.
Used in Cell Biology Research:
BTO-1 is used as a cell biology research tool to study the role of Plk1 in cell division, mitosis, and the assembly of the contractile ring. Its effects on Rho and Rho-GEF recruitment provide insights into the cellular processes that are essential for proper cell division and may help in understanding the underlying mechanisms of various diseases related to cell division abnormalities.
Biochem/physiol Actions
BTO-1 is a polo-like kinase (Plk) inhibitor.
Check Digit Verification of cas no
The CAS Registry Mumber 40647-02-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,6,4 and 7 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 40647-02:
(7*4)+(6*0)+(5*6)+(4*4)+(3*7)+(2*0)+(1*2)=97
97 % 10 = 7
So 40647-02-7 is a valid CAS Registry Number.
40647-02-7Relevant academic research and scientific papers
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1
Pearson, Russell J.,Blake, David G.,Mezna, Mokdad,Fischer, Peter M.,Westwood, Nicholas J.,McInnes, Campbell
, p. 1107 - 4,1116 (2018/07/02)
The polo kinase family are important oncology targets that act in regulating entry into and progression through mitosis. Structure-guided discovery of a new class of inhibitors of Polo-like kinase 1 (PLK1) catalytic activity that interact with Cys67 of th
BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
-
Page/Page column 26, (2008/06/13)
The present invention relates to the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are each independently H, N02, CF3, SCF
